Breathe Well Live Well
 RTT News |
GlaxoSmithKline Boosts Stake In Theravance To 27%
NASDAQ The move is said to be on the potential success of asthma drug Relovair, which is believed to be the successor of Seretide/Advair that logged sales of roughly $8.1 billion in 2011. Relovair is developed by Theravance and GlaxoSmithKline and is a … GlaxoSmithKline to Increase Its Ownership in Theravance GlaxoSmithKline invests $213M in Theravance Inc. Glaxo Lifts Theravance Stake |
View full post on asthma – Google News
|
GSK, Theravance Report Mixed-Bag of Data for Relovair in COPD, Asthma
Genetic Engineering News GlaxoSmithKline (GSK) and Theravance are reporting mostly positive results from two studies for Relovair in chronic obstructive pulmonary disease (COPD) and asthma. Relovair met its primary endpoint in one of two replicate studies in COPD comparing it … GSK and Theravance Announce Completion of the Relovair(TM)* Registrational … GSK lung drug has mixed results but filing on track GSK's Relovair on track for COPD drug filing; talks on asthma in US ongoing |
View full post on asthma – Google News
|
Glaxo and Theravance Suffer Setback
Zacks.com In the asthma studies, Relovair showed an encouraging efficacy profile but was associated with several side-effects, like headache, nasopharyngitis, upper respiratory tract infection, bronchitis, cough, oropharyngeal pain and influenza. … |
View full post on asthma – Google News
 Telegraph.co.uk |
GSK and Theravance to file COPD/asthma drug
The Pharma Letter For asthma, GSK plans to submit an application in Europe in mid-2012 and will continue discussions with the Food and Drug Administration on the regulatory requirements for a US asthma indication. Despite some mixed clinical trial results with Relovair … GSK, Theravance report completion of Relovair studies in COPD and asthma GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … Theravance Falls Most in 3 Years After Glaxo Drug Fails |
View full post on asthma – Google News
 Visit Bulgaria |
GSK, Theravance report completion of Relovair studies in COPD and asthma
Pharmaceutical Business Review GlaxoSmithKline (GSK) and Theravance have announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair used to treat chronic obstructive pulmonary disease (COPD) and asthma. … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … Theravance Falls Most in 3 Years After Glaxo Drug Fails Glaxo on the slide after trials setback for asthma drug |
View full post on asthma – Google News
Visit Bulgaria |
Theravance Falls Most in 3 Years After Glaxo Drug Fails
BusinessWeek The company, based in South San Francisco, California, said in a statement today that Relovair, its drug for asthma and chronic obstructive pulmonary disease, proved no better than Glaxo's Seretide in a clinical trial. Relovair is “the most important … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … Glaxo on the slide after trials setback for asthma drug Theravance Shares Slide on Lung Drug Deaths |
View full post on asthma – Google News
|
GSK to seek approval of Theravance lung drug
San Francisco Business Times (blog) GlaxoSmithKline will seek approval of the COPD drug Relovair in the United States and Europe in mid-year, and it and partner Theravance Inc. will continue to talk to regulators about also using the drug for asthma patients. … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … Glaxo set to submit Relovair to regulatory authorities GSK aims to file new lung drug Relovair in mid-2012 |
View full post on asthma – Google News
|
Theravance Poised to Jump
Minyanville.com The drug, Relovair, is being tested as a once-daily treatment for chronic obstructive pulmonary disease and asthma. Glaxo sees it as a successor to Advair, … |
View full post on asthma – Google News
|
GlaxoSmithKline Grows Theravance Stake: Investing in the Pipeline
Seeking Alpha Chief among the products of their collaboration to date is Relovair, heir to the throne of Advair, GSK's best-selling medicine for asthma attacks and COPD. … |
View full post on asthma – Google News
|
Theravance Reports Third Quarter 2010 Financial Results
MarketWatch (press release) "The RELOVAIR(TM) Phase 3 programs in COPD and asthma are progressing well and have now enrolled over 8000 patients. Last month, preclinical and Phase 2a … |
View full post on asthma – Google News